Ozanimod
As of the edition of 20 October 2026, Ozanimod is a small molecule: marketed, first approved in 2020 (US); acts on S1PR1; US protection ends in 2038.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Small molecule
- Brand name
- Zeposia
- First approved
- 25 March 2020 (US)
- Approvals on record
- 8 in 5 regions
- Holder of the most recent approval
- Bristol Myers Squibb
- Registered trials
- 51, 14 stopped early
- Disease areas
- Digestive system; Immune system; Nervous system; Infections; Blood and lymph; Cancer
US protection
US protection ends in 2038.
The last listed US drug-substance patent ends in 2038. The application that gives this date is held by Bristol Myers Squibb.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product15 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 15 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Ozanimod.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| S1PR1 | Sphingosine 1-phosphate receptor 1 | P21453 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 14 | 2 | 6 | 3 |
| Phase 1 | 11 | 11 | 0 | 0 |
| Phase 2 | 4 | 2 | 1 | 1 |
| Phase 3 | 16 | 8 | 2 | 6 |
| Phase 4 | 6 | 0 | 2 | 4 |
| All trials | 51 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Originator and Lead sponsor of trials | 2012 to now |